Patents by Inventor Shunsuke Iwamoto

Shunsuke Iwamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11127771
    Abstract: Solid-state imaging devices, methods of producing a solid-state imaging device, and electronic apparatuses are provided. More particularly, a solid-state image device includes a silicon substrate, and at least a first photodiode formed in the silicon substrate. The device also includes an epitaxial layer with a first surface adjacent a surface of the silicon substrate, and a transfer transistor with a gate electrode that extends from the at least a first photodiode to a second surface of the epitaxial layer opposite the first surface. In further embodiments, a solid-state imaging device with a plurality of pixels formed in a second semiconductor substrate wherein the pixels are symmetrical with respect to a center point is provided. A floating diffusion is formed in an epitaxial layer, and a plurality of transfer gate electrodes that are each electrically connected to the floating diffusion by one of the transfer gate electrodes is provided.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: September 21, 2021
    Assignee: SONY CORPORATION
    Inventors: Yusuke Tanaka, Toshifumi Wakano, Keiji Tatani, Takashi Nagano, Hayato Iwamoto, Keiichi Nakazawa, Tomoyuki Hirano, Shinpei Yamaguchi, Shunsuke Maruyama
  • Patent number: 10724028
    Abstract: The invention provides a ligand-bonded fiber in which a ligand having affinity for a cell membrane receptor is immobilized on a fiber precursor, and a cell culture substrate capable of repeating ex vivo amplification of a cell expressing a cell membrane receptor by using the ligand-bonded fiber.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: July 28, 2020
    Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Makiko Umezaki, Takahiro Kishioka, Taito Nishino, Ayako Aihara, Shunsuke Iwamoto, Daisuke Sakuma
  • Patent number: 10385052
    Abstract: Novel tricyclic compounds which have JAK inhibitory activities are useful for prevention, treatment or improvement of autoimmune diseases, inflammatory diseases and allergic diseases are provided. Novel tricyclic compound represented by the formula (I), the formula (II) or the formula (III) (wherein: each of A1, A2 and A3 is a cyclohexane-1,4-diyl group or the like; each of L1, L2 and L3 is a methylene group or the like; each of X1 and X3 is O or NH; each of R1 and R3 is a cyano C1-6 haloalkyl group or the like; and R2 is an aromatic heterocyclic group), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: August 20, 2019
    Assignee: Nissan Chemical Corporation
    Inventors: Tsuneo Watanabe, Keiji Takahashi, Keishi Hayashi, Takanori Nakamura, Masataka Minami, Kazunori Kurihara, Akio Yamamoto, Takuya Nishimura, Miyuki Uni, Toshihiko Kamiyama, Shunsuke Iwamoto
  • Publication number: 20180099966
    Abstract: Novel tricyclic compounds which have JAK inhibitory activities are useful for prevention, treatment or improvement of autoimmune diseases, inflammatory diseases and allergic diseases are provided. Novel tricyclic compound represented by the formula (I), the formula (II) or the formula (III) (wherein: each of A1, A2 and A3 is a cyclohexane-1,4-diyl group or the like; each of L1, L2 and L3 is a methylene group or the like; each of X1 and X3 is 0 or NH; each of R1 and R3 is a cyano C1-6 haloalkyl group or the like; and R2 is an aromatic heterocyclic group), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.
    Type: Application
    Filed: December 13, 2017
    Publication date: April 12, 2018
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Tsuneo Watanabe, Keiji Takahashi, Keishi Hayashi, Takanori Nakamura, Masataka Minami, Kazunori Kurihara, Akio Yamamoto, Takuya Nishimura, Miyuki Uni, Toshihiko Kamiyama, Shunsuke Iwamoto
  • Patent number: 9890165
    Abstract: Novel tricyclic compounds which have JAK inhibitory activities are useful for prevention, treatment or improvement of autoimmune diseases, inflammatory diseases and allergic diseases are provided. Novel tricyclic compound represented by the formula (I), the formula (II) or the formula (III) (wherein: each of A1, A2 and A3 is a cyclohexane-1,4-diyl group or the like; each of L1, L2 and L3 is a methylene group or the like; each of X1 and X3 is O or NH; each of R1 and R3 is a cyano C1-6 haloalkyl group or the like; and R2 is an aromatic heterocyclic group), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: February 13, 2018
    Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Tsuneo Watanabe, Keiji Takahashi, Keishi Hayashi, Takanori Nakamura, Masataka Minami, Kazunori Kurihara, Akio Yamamoto, Takuya Nishimura, Miyuki Uni, Toshihiko Kamiyama, Shunsuke Iwamoto
  • Publication number: 20180010115
    Abstract: The invention provides a ligand-bonded fiber in which a ligand having affinity for a cell membrane receptor is immobilized on a fiber precursor, and a cell culture substrate capable of repeating ex vivo amplification of a cell expressing a cell membrane receptor by using the ligand-bonded fiber.
    Type: Application
    Filed: October 30, 2015
    Publication date: January 11, 2018
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Makiko UMEZAKI, Takahiro KISHIOKA, Taito NISHINO, Ayako AIHARA, Shunsuke IWAMOTO, Daisuke SAKUMA
  • Publication number: 20170044161
    Abstract: Novel tricyclic compounds which have JAK inhibitory activities are useful for prevention, treatment or improvement of autoimmune diseases, inflammatory diseases and allergic diseases are provided. Novel tricyclic compound represented by the formula (I), the formula (II) or the formula (III) (wherein each of A1, A2 and A3 is a cyclohexane-1,4-diyl group or the like; each of L1, L2 and L3 is a methylene group or the like: each of X1 and X3 is O or NH; each of R1 and R3 is a cyano C1-6 haloalkyl group or the like; and R2 is an aromatic heterocyclic group), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.
    Type: Application
    Filed: May 11, 2015
    Publication date: February 16, 2017
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Tsuneo WATANABE, Keiji TAKAHASHI, Keishi HAYASHI, Takanori NAKAMURA, Masataka MINAMI, Kazunori KURIHARA, Akio YAMAMOTO, Takuya NISHIMURA, Miyuki UNI, Toshihiko KAMIYAMA, Shunsuke IWAMOTO
  • Patent number: 9527828
    Abstract: An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various hematopoietic disorders is provided. A method for expanding hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises culturing hematopoietic stem cells and/or hematopoietic progenitor cells ex vivo in the presence of a compound represented by the formula (I) (wherein X, Y, X, Ar1, R1, R2, R3, R4, R5, R6 and R7 are defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.
    Type: Grant
    Filed: December 6, 2008
    Date of Patent: December 27, 2016
    Assignees: Nissan Chemical Industries, Ltd., ReproCELL Incorporated
    Inventors: Taito Nishino, Norihisa Ishiwata, Katsuaki Miyaji, Shunsuke Iwamoto, Yasuyuki Asai, Makiko Yui
  • Patent number: 9328085
    Abstract: An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells is provided, containing a compound represented by the formula (I): (wherein X, Y, Z, Ar1 , R1, R2, R3, R4, R5, R6 and R7 are as defined in the description), a tautomer, amide, ester, or pharmaceutically acceptable salt of the compound or a solvate thereof, which can expand hematopoietic stem cells and/or hematopoietic progenitor cells.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: May 3, 2016
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Taito Nishino, Shunsuke Iwamoto, Katsuaki Miyaji
  • Patent number: 9102602
    Abstract: The object of the present invention is to provide a novel method for producing an isothiocyanate compound having a carboxyl group(s) by a reaction of the corresponding amino compound having a carboxyl group(s), thiocarbonyldiimidazole and a base, in one step with high purity. An amino compound having a carboxyl group(s) is reacted with thiocarbonyldiimidazole in a solvent in the presence of a base to obtain an isothiocyanate compound having a carboxyl group(s).
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: August 11, 2015
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Junko Takada, Shunsuke Iwamoto, Satoshi Nakano
  • Patent number: 8946286
    Abstract: A novel organic amine salt or salt with quaternary ammonium ion of 3-{[((2E)-2-{1-[5-(4-t-butylphenyl)-4-hydroxy-3-thienyl]ethylidene}hydrazino)carbonothioyl]amino}benzoic acid having useful properties as a drug is provided. A novel organic amine or salt with quaternary ammonium ion of 3-{[((2E)-2-{1-[5-(4-t-butylphenyl)-4-hydroxy-3-thienyl]ethylidene}hydrazino)carbonothioyl]amino}benzoic acid, a method for producing the organic amine salt or the salt with quaternary ammonium ion and a platelet increasing agent.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: February 3, 2015
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Shunsuke Iwamoto, Satoshi Nakano, Mariko Ishida, Masao Yamamoto, Kazuya Takeuchi
  • Patent number: 8889732
    Abstract: Fused heterocyclic compounds useful for prevention, treatment or improvement of diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R1 is an aryl group fused to a saturated ring or the like, A, B, L1, R2, L2, L3, Y, L4, R3 and X are defined in the description), a tautomer, prodrug or a pharmaceutically acceptable salt of the compound or a solvate thereof.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: November 18, 2014
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Yukihiro Shigeta, Shingo Umezawa, Shunsuke Iwamoto, Takanori Nakamura
  • Publication number: 20140227780
    Abstract: An agent for inducing production of megakaryocytes and/or platelets from pluripotent stem cells which is useful for treatment of disease accompanied by a decrease in platelets is provided. A method for producing megakaryocytes and/or platelets, including separating hematopoietic progenitor cells from the septal cells in sac-like structures produced by pluripotent stem cells, and culturing the hematopoietic progenitor cells ex vivo in the presence of a compound represented by the formula (I) where R1 to R7, W, X, Y, Z, Ar1 and n are as defined in the description to differentiate them into megakaryocytes and/or platelets.
    Type: Application
    Filed: October 3, 2012
    Publication date: August 14, 2014
    Applicants: NISSAN CHEMICAL INDUSTRIES, LTD., The UNIVERSITY OF TOKYO
    Inventors: Taito Nishino, Takanori Nakamura, Shunsuke Iwamoto, Koji Eto, Hiromitsu Nakauchi, Kayoko Tsuji
  • Patent number: 8658686
    Abstract: Novel therapeutic agents for myeloma are provided. A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): wherein R1 is C1-C6 alkyl, C1-C6 alkyl substituted with R17, C1-C6 haloalkyl, phenyl, phenyl substituted with a R11's or the like, R2 is a hydrogen atom, C1-C6 alkyl, phenyl or phenyl optionally substituted with e R21's or the like, R3 is a hydrogen atom or the like, X is a single bond or ā€”(CR6R7)nā€”, each of R4 and R5 is independently C1-C6 alkyl or the like, R6 and R7 are hydrogen atoms or C1-C6 alkyl, R8 is phenyl, phenyl optionally substituted with k R81's or the like, a tautomer of the compound or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: February 25, 2014
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Taito Nishino, Katsuaki Miyaji, Shunsuke Iwamoto, Takumi Mikashima, Koichiro Saruhashi, Yo Kishikawa
  • Publication number: 20140051857
    Abstract: A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
    Type: Application
    Filed: October 28, 2013
    Publication date: February 20, 2014
    Applicant: Nissan Chemical Industries Limited
    Inventors: Shingo OWADA, Shunsuke Iwamoto, Kazufumi Yanagihara, Katsuaki Miyaji, Takanori Nakamura, Norihisa Ishiwata, Yutaka Hirokawa
  • Publication number: 20130253204
    Abstract: Novel therapeutic agents for myeloma are provided. A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): wherein R1 is C1-C6 alkyl, C1-C6 alkyl substituted with R17, C1-C6 haloalkyl, phenyl, phenyl substituted with a R11's or the like, R2 is a hydrogen atom, C1-C6 alkyl, phenyl or phenyl optionally substituted with e R21's or the like, R3 is a hydrogen atom or the like, X is a single bond or ā€”(CR6, R7)nā€”, each of R4 and R5 is independently C1-C6 alkyl or the like, R6 and R7 are hydrogen atoms or C1-C6 alkyl, R8 is phenyl, phenyl optionally substituted with k R81's or the like, a tautomer of the compound or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.
    Type: Application
    Filed: December 1, 2011
    Publication date: September 26, 2013
    Applicant: Nissan Chemical Industries, Ltd.
    Inventors: Taito Nishino, Katsuaki Miyaji, Shunsuke Iwamoto, Takumi Mikashima, Koichiro Saruhashi, Yo Kishikawa
  • Publication number: 20130245305
    Abstract: The object of the present invention is to provide a novel method for producing an isothiocyanate compound having a carboxyl group(s) by a reaction of the corresponding amino compound having a carboxyl group(s), thiocarbonyldiimidazole and a base, in one step with high purity. An amino compound having a carboxyl group(s) is reacted with thiocarbonyldiimidazole in a solvent in the presence of a base to obtain an isothiocyanate compound having a carboxyl group(s).
    Type: Application
    Filed: November 29, 2010
    Publication date: September 19, 2013
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Junko Takada, Shunsuke Iwamoto, Satoshi Nakano
  • Publication number: 20130245255
    Abstract: An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells containing a compound represented by the formula (I) (wherein X, Y, Z, Ar1, R1, R2, R3, R4, R5, R6 and R7 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof, which can expand hematopoietic stem cells and/or hematopoietic progenitor cells.
    Type: Application
    Filed: May 2, 2013
    Publication date: September 19, 2013
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Taito NISHINO, Shunsuke IWAMOTO, Katsuaki MIYAJI
  • Publication number: 20130217894
    Abstract: A novel organic amine salt or salt with quaternary ammonium ion of 3-{[((2E)-2-{1-[5-(4-t-butylphenyl)-4-hydroxy-3-thienyl]ethylidene}hydrazino)carbonothioyl]amino}benzoic acid having useful properties as a drug is provided. A novel organic amine or salt with quaternary ammonium ion of 3-{[((2E)-2-{1-[5-(4-t-butylphenyl)-4-hydroxy-3-thienyl]ethylidene}hydrazino)carbonothioyl]amino}benzoic acid, a method for producing the organic amine salt or the salt with quaternary ammonium ion and a platelet increasing agent.
    Type: Application
    Filed: November 1, 2011
    Publication date: August 22, 2013
    Applicant: Nissan Chemical Industries, Ltd.
    Inventors: Shunsuke Iwamoto, Satoshi Nakano, Mariko Ishida, Masao Yamamoto, Kazuya Takeuchi
  • Publication number: 20130012708
    Abstract: A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Applicant: Nissan Chemical Industries Limited
    Inventors: Shingo Owada, Shunsuke Iwamoto, Kazufumi Yanagihara, Katsuaki Miyaji, Takanori Nakamura, Norihisa Ishiwata, Yutaka Hirokawa